The Effect of Neutrophil Lymphocyte Ratio on Prognosis in Patients with Metastatic Renal Cell Carcinoma

Year 2021, , 134 - 139, 30.04.2021

Ferhat Ekinci , Atike Pinar Erdoğan , Ahmet Dirican , Gamze Göksel

https://doi.org/10.47493/abantmedj.2021.43

Abstract

Purpose: The prognostic relationship between malignant tumors and neutrophil lymphocyte ratio (NLR) has been investigated in many cancers, but since there are not enough studies in RCC patients, it was aimed to investigate the prognostic relationship between these patients and NLR in our own hospital data.
Methods: Records of 38 patients diagnosed with metastatic RCC were analyzed retrospectively. ROC analysis was performed to determine the threshold value of NLR in patients and according to the result of the test, the patients were divided into two groups as NLR <2.14 and NLR > 2.14. The two groups were compared in terms of disease-specific survival.
Results: Overall survival calculated in all patients was 52 months (95% CI: 35-68, std: 6.5). In 14 (36.8%) patients who were lower than the 2.14 cut off value (<2.14) obtained in the ROC analysis performed to determine the threshold value in the NLR, the mean survival (OS) was 89 months, while the higher (> 2, 14) In 24 (63.2%) patients, OS was detected for 21 months, and this result was reported to be statistically significant (p; 0.03).
Conclusion: NLR may be OS related in RCC. However, more studies are needed to determine their routine use.

Keywords

Renal cell carcinoma, neutrophil to lymphocyte ratio, prognosis

Thanks

Dear Editor, Please find attached the paper, ‘’ The Effect of Neutrophil Lymphocyte Ratio on Prognosis in Patients with Metastatic Renal Cell Carcinoma by Ferhat Ekinci, Ahmet Dirican, Atike Pınar Erdoğan and Gamze Göksel which we would like to submit for possible publication to the ‘ Abant Medical Journal’. We think that with the increase in the number of studies on this subject, it will strengthen its place as a cheap, accessible and reliable parameter that can be used in RCC and all other cancers. For any information concerning this manuscript, please contact me preferably by e-mail at [e-mail]. Thank you for your consideration of this manuscript. I look forward to hearing from you soon. Yours sincerely, Dr. Ferhat Ekinci

Metastatik Renal Hücreli Karsinom Tanılı Hastalarımızda Nötrofil Lenfosit Oranının Prognoz Üzerine Etkisi

Abstract

Amaç: Maliğn tümörlerle nötrofil lenfosit oranı (NLO) arasındaki prognostik ilişki bir çok kanserde araştırılmış ancak RHK hastalarında yeteri kadar çalışma olmadığı için kendi hastanemiz verilerinde bu hastalar ile NLO arasındaki prognostik ilişkiyi araştırılması amaçlanmıştır.
Yöntem: Metastatik RHK tanılı 38 hastanın kayıtları retrospektif olarak incelendi. Hastalarda NLO eşik değerinin belirlenmesi için ROC analizi yapıldı ve testten çıkan sonuca göre hastalar NLO<2,14 ve NLO≥2,14 olmak üzere iki gruba ayrıldı. İki grup, hastalığa özgü sağ kalım açısından karşılaştırıldı.
Bulgular: Tüm hastalarda hesaplanan genel sağ kalım 52 ay (% 95 CI:35-68, std:6,5) olarak saptandı. NLO’da eşik değer belirleyebilmek için yapılan ROC analizinde elde edilen 2,14 cut off değerinden düşük olan (< 2,14) 14 (% 36,8) hastada ortalama sağ kalım (OS) 89 ay iken, yüksek olan (>2,14) 24 (% 63,2) hastada ise OS 21 ay saptanmış ve bu sonuç istatistiksel olarak anlamlı (p;0,03) raporlanmıştır.
Sonuç: NLO, RHK'de OS ile ilişkili olabilir. Bununla birlikte, rutin kullanımlarını belirlemek için daha fazla çalışmaya ihtiyaç vardır.

Keywords

renal hücreli karsinom, nötrofil lenfosit oranı, prognoz

References

• 1- Peinemann, F., Unverzagt, S., Hadjinicolaou, A. V., & Moldenhauer, I. (2019). Immunotherapy for metastatic renal cell carcinoma: A systematic review. Journal of Evidence‐Based Medicine, 12(4), 253-262..
• 2- Society AC. Cancer facts and figures. https://www.cancer.org/ research/cancer-facts-statistics/all-cancer-facts-figures/ cancer-facts-figures-2017.html2017
• 3- Jonasch, E., Gao, J., & Rathmell, W. K. (2014). Renal cell carcinoma. Bmj, 349, g4797.
• 4- Dirican, A., Kucukzeybek, Y., Erten, C., Somali, I., Demir, L., Can, A., … & Köseoglu, M. (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14(3), 2101 5.
• 5- Roxburgh, C. S., & McMillan, D. C. (2010). Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future oncology, 6(1), 149-163.
• 6- Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883-899.
• 7- Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., ... & Tannock, I. F. (2014). Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute, 106(6).
• 8- Boissier, R., Campagna, J., Branger, N., Karsenty, G., & Lechevallier, E. (2017, April). The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review. In Urologic Oncology: Seminars and Original Investigations (Vol. 35, No. 4, pp. 135-141). Elsevier.
• 9- Huszno, Joanna, et al. "The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma." Oncology 97.1 (2019): 7-17.
• 10- Widz, D., Mitura, P., Buraczynski, P., Plaza, P., Bar, M., Cabanek, M., ... & Bar, K. (2020). Preoperative neutrophil-lymphocyte ratio as a predictor of overall survival in patients with localized renal cell carcinoma. Urology Journal, 17(1), 30-35.
• 11- Bilen MA, Dutcher GMA, Liu Y et al (2018) Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer 16(3):e563–e575
• 12- Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 373(19):1803–1813
• 13- Suzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2020). C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. International Journal of Clinical Oncology, 25(1), 135-144.
• 14- Hizal, M., Sendur, M. A., Yasar, H. A., Bir Yucel, K., Arslan, C., Ucar, G., ... & Bilgin, B. (2020). Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice, 1078155219900908.
• 15- European Network of Cancer Registries: Eurocim version 4.0. 200: Lyon, France.
• 16- Kim SC, Sun KH, Choi DH, et al. Prediction of Long-Term Mortality Based on Neutrophil- Lymphocyte Ratio After Percutaneous Coronary Intervention. Am J Med Sci. 2016;351(5):467-72.
• 17- Quiros-Roldan E, Raffetti E, Donato F, et al. Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV- Infected Patients: A Population-Based Cohort Study. PLoS One. 2016;11(5):e0154900
• 18- Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883-899.
• 19- Nielsen, B. S., Timshel, S., Kjeldsen, L., Sehested, M., Pyke, C., Borregaard, N., & Danø, K. (1996). 92 kDa type IV collagenase (MMP‐9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. International journal of cancer, 65(1), 57-62.
• 20- Bellocq, A., Antoine, M., Flahault, A., Philippe, C., Crestani, B., Bernaudin, J. F., ... & Cadranel, J. (1998). Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. The American journal of pathology, 152(1), 83.
• 21- Tazzyman, S., Lewis, C. E., & Murdoch, C. (2009). Neutrophils: key mediators of tumour angiogenesis. International journal of experimental pathology, 90(3), 222-231..
• 22- Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. nature, 454(7203), 436-444.
• 23- Sparmann, A., & Bar-Sagi, D. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer cell, 6(5), 447-458
• 24- Vakkila, J., & Lotze, M. T. (2004). Inflammation and necrosis promote tumour growth. Nature Reviews Immunology, 4(8), 641-648.